Telehealth firm Hims & Hers pulled a compounded version of Novo Nordisk’s Wegovy after legal pressure from the maker and mounting regulatory scrutiny. Novo Nordisk challenged the product as an infringing copy of its GLP‑1, prompting Hims to stop sales days after launch. Simultaneously, U.S. authorities signaled enforcement interest: federal officials have sought a Department of Justice review into Hims’ marketing of non‑approved GLP‑1 products. The episode underscores an intensifying enforcement posture around mass compounding and copycat forms of branded obesity drugs. Companies selling or compounding GLP‑1 analogs face legal and regulatory risk, and telehealth distributors could see rapid policy action that affects distribution channels and commercial strategies.